Zymeworks (ZYME) has disclosed a new risk, in the Costs category.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zymeworks may face financial strain due to the costs and complexities following its transition to a Delaware corporation. The company’s decision to not proceed with certain Post-Arrangement Transactions, as originally planned, due to potential negative tax consequences could lead to operational and tax inefficiencies in its current structure. Furthermore, substantial non-recurring expenses incurred during the Redomicile Transactions may not be quickly recouped, posing a risk to Zymeworks’ short-term financial health and its ability to achieve the anticipated benefits of its corporate reorganization.
Overall, Wall Street has a Moderate Buy consensus rating on ZYME stock based on 2 Buys and 1 Hold.
To learn more about Zymeworks’ risk factors, click here.